Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
Sponsor: Yale University
Summary
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-03-01
Completion Date
2026-06-30
Last Updated
2025-03-04
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin 25 mg vs Placebo
Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
Empagliflozin 10 MG
Chronic Study- Empagliflozin 10 mg for 8 weeks
Locations (1)
Yale University
New Haven, Connecticut, United States